文献速递创伤骨科骨质疏松与代谢性骨病

特立帕肽治疗双膦酸盐相关非典型股骨骨折患者

Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur.
PubMed 文献 · Osteoporos Int · 2017-10-30

Fix-IT 随机先导试验纳入 13 例双膦酸盐相关非典型股骨骨折女性,随机分为即刻特立帕肽组与延迟 6 个月特立帕肽组,均随访 12 个月。结果显示即刻组在影像学愈合复合评分和桡骨远端 1/3 骨密度下降方面有更优趋势,不良事件无差异,但样本量小、需谨慎解读。

要点

  • 即刻特立帕肽组 6 个月和 12 个月影像学愈合复合评分均高于延迟组,呈更优趋势。
  • 即刻组 12 个月桡骨远端 1/3 骨密度下降幅度小于延迟组,呈更轻趋势。
  • 两组不良事件无差异,延迟组出现 1 例植入物失败。

核心结论

  • 即刻特立帕肽治疗相比延迟治疗有更优的初步信号,但由于非典型股骨骨折是罕见事件且纳入患者数量少,结果必须谨慎解读。

研究设计与样本

  • Fix-IT 随机先导临床试验纳入 13 例非典型股骨骨折女性,随机分为即刻特立帕肽组与延迟 6 个月特立帕肽组,均随访 12 个月并接受特立帕肽治疗。

主要发现

  • 影像学愈合复合评分:即刻组 6 个月 12.6 vs 延迟组 11.2,12 个月 15.4 vs 13.2,呈即刻组更优趋势。
  • 桡骨远端 1/3 骨密度 12 个月变化:即刻组 -1.9% vs 延迟组 -6.1%,即刻组下降更少。
  • 不良事件两组无差异;延迟组出现 1 例植入物失败。

关键数值与推荐

  • 影像学骨愈合评分范围为 1 分(无愈合)至 4 分(完全愈合),在 6 个月和 12 个月评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 非典型股骨骨折是罕见事件,且仅纳入少量患者,结果必须谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The Fracture Improvement with Teriparatide (Fix-IT) study randomized 13 women with an atypical femur fracture to immediate vs delayed teriparatide therapy; all were followed for 12 months. Results suggested a trend for superior healing and lesser bone mineral density declines in the immediate vs delayed group with no differences in adverse events. PURPOSE: Little clinical data are available on the use of teriparatide for the treatment of bisphosphonate-associated atypical femur fractures (AFF). The goal of the Fix-IT study was to determine if immediate therapy with teriparatide was superior for fracture healing after an AFF compared to a 6-month delay in teriparatide therapy. METHODS: This randomized pilot clinical trial included 13 women with an AFF who were randomized to immediate teriparatide vs a delay of 6 months. All were followed for 12 months on teriparatide. The primary outcomes included individual and composite measures of radiologic bone healing (scored 1 point [no healing] to 4 points [complete healing]) at 6 and 12 months. Secondary outcomes included bone mineral density of the unfractured contralateral hip, spine, 1/3 distal radius, and adverse events. RESULTS: We found there was a trend for superior healing with the composite score (12.6 vs 11.2 at 6 months and 15.4 vs 13.2 at 12 months), and lesser bone mineral density declines at the 1/3 distal radius (12-month change - 1.9 vs - 6.1%) in the immediate vs the delayed group. There were no differences in adverse events. There was one implant failure in the delayed group. CONCLUSIONS: There is a preliminary signal for greater improvements with immediate teriparatide therapy vs delayed therapy. However, because an AFF is a rare event, and only a small number of patients were included, the results must be interpreted with caution.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Greenspan SL, Vujevich K, Britton C, et al. Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur. Osteoporos Int. 2017. PMID: 29085957. doi:10.1007/s00198-017-4286-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。